End-of-day quote
Shenzhen S.E.
03:30:00 26/04/2024 am IST
|
5-day change
|
1st Jan Change
|
24.93
CNY
|
+0.69%
|
|
-0.32%
|
-4.48%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
3,928
|
4,986
|
3,720
|
3,943
|
3,917
|
4,810
|
Enterprise Value (EV)
1 |
2,461
|
3,321
|
2,178
|
2,326
|
1,969
|
2,623
|
P/E ratio
|
21.3
x
|
26.5
x
|
408
x
|
32.3
x
|
41.7
x
|
13.2
x
|
Yield
|
1.39%
|
1.1%
|
0.49%
|
1.39%
|
1.41%
|
2.3%
|
Capitalization / Revenue
|
2.61
x
|
3.09
x
|
3.26
x
|
3.61
x
|
3.42
x
|
4.17
x
|
EV / Revenue
|
1.64
x
|
2.06
x
|
1.91
x
|
2.13
x
|
1.72
x
|
2.27
x
|
EV / EBITDA
|
11.1
x
|
13.6
x
|
21.2
x
|
26.7
x
|
15.7
x
|
14.6
x
|
EV / FCF
|
-1,387
x
|
21.9
x
|
-17
x
|
273
x
|
6.52
x
|
118
x
|
FCF Yield
|
-0.07%
|
4.56%
|
-5.87%
|
0.37%
|
15.3%
|
0.85%
|
Price to Book
|
1.22
x
|
1.13
x
|
0.86
x
|
0.89
x
|
0.9
x
|
0.97
x
|
Nbr of stocks (in thousands)
|
1,82,455
|
1,82,455
|
1,82,455
|
1,82,455
|
1,83,993
|
1,84,277
|
Reference price
2 |
21.53
|
27.33
|
20.39
|
21.61
|
21.29
|
26.10
|
Announcement Date
|
24/03/19
|
22/04/20
|
23/03/21
|
24/03/22
|
23/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,504
|
1,615
|
1,141
|
1,092
|
1,147
|
1,153
|
EBITDA
1 |
222.1
|
244.3
|
103
|
87.19
|
125.5
|
179.4
|
EBIT
1 |
167.9
|
184.3
|
40.29
|
28.66
|
61.05
|
113.6
|
Operating Margin
|
11.17%
|
11.41%
|
3.53%
|
2.62%
|
5.32%
|
9.85%
|
Earnings before Tax (EBT)
1 |
214
|
216.8
|
30.93
|
137.1
|
118.4
|
420.2
|
Net income
1 |
185
|
188.1
|
8.615
|
122.1
|
93.61
|
361.8
|
Net margin
|
12.3%
|
11.65%
|
0.76%
|
11.18%
|
8.16%
|
31.38%
|
EPS
2 |
1.010
|
1.030
|
0.0500
|
0.6700
|
0.5100
|
1.970
|
Free Cash Flow
1 |
-1.775
|
151.4
|
-128
|
8.514
|
301.9
|
22.21
|
FCF margin
|
-0.12%
|
9.37%
|
-11.22%
|
0.78%
|
26.33%
|
1.93%
|
FCF Conversion (EBITDA)
|
-
|
61.97%
|
-
|
9.77%
|
240.58%
|
12.38%
|
FCF Conversion (Net income)
|
-
|
80.46%
|
-
|
6.97%
|
322.51%
|
6.14%
|
Dividend per Share
2 |
0.3000
|
0.3000
|
0.1000
|
0.3000
|
0.3000
|
0.6000
|
Announcement Date
|
24/03/19
|
22/04/20
|
23/03/21
|
24/03/22
|
23/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,467
|
1,665
|
1,542
|
1,617
|
1,949
|
2,187
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.78
|
151
|
-128
|
8.51
|
302
|
22.2
|
ROE (net income / shareholders' equity)
|
5.88%
|
4.93%
|
0.2%
|
2.8%
|
2.14%
|
7.82%
|
ROA (Net income/ Total Assets)
|
2.76%
|
2.51%
|
0.49%
|
0.35%
|
0.73%
|
1.28%
|
Assets
1 |
6,696
|
7,504
|
1,761
|
34,818
|
12,860
|
28,222
|
Book Value Per Share
2 |
17.60
|
24.20
|
23.60
|
24.20
|
23.60
|
26.90
|
Cash Flow per Share
2 |
8.480
|
9.270
|
8.560
|
9.050
|
9.750
|
10.90
|
Capex
1 |
104
|
90.5
|
101
|
88.2
|
40.9
|
61.7
|
Capex / Sales
|
6.95%
|
5.6%
|
8.82%
|
8.08%
|
3.57%
|
5.35%
|
Announcement Date
|
24/03/19
|
22/04/20
|
23/03/21
|
24/03/22
|
23/03/23
|
21/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -4.48% | 634M | | +19.62% | 43.34B | | +20.44% | 21.96B | | +10.86% | 14.09B | | +13.07% | 13.64B | | +37.46% | 11.43B | | -8.59% | 6.86B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +8.46% | 5.22B |
Generic Pharmaceuticals
|